ARTA
AUTL

A.R.T. Advisors’s Autolus Therapeutics AUTL Stock Holding History

A.R.T. Advisors’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-17,816
Closed -$235K – 125
2019
Q4 		$235K Buy
17,816
+5,600
+46% +$73.3K 0.01% 1113
2019
Q3 		$152K Buy
+12,216
New +$161K 0.01% 1221

Other funds holding AUTL

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

A.R.T. Advisors's AUTL Position: Q1 2020 in Review

A.R.T. Advisors sold out of Autolus Therapeutics (AUTL) in Q1 2020, closing a stake of 17,816 shares — an estimated $235K sold.

A.R.T. Advisors first reported a position in AUTL in Q3 2019 and held it in 2 quarters. The position peaked at $235K in Q4 2019. 51 funds tracked by Wall St. Rank hold AUTL as of Q1 2020.

  • A.R.T. Advisors reported no remaining Autolus Therapeutics position as of Q1 2020 after selling out during the quarter.
  • A.R.T. Advisors sold 17,816 Autolus Therapeutics shares in Q1 2020, an estimated $235K.
  • A.R.T. Advisors first reported a position in Autolus Therapeutics in Q3 2019 and held it in 2 quarters.
  • A.R.T. Advisors's Autolus Therapeutics position peaked at $235K in Q4 2019.
  • 51 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.